Crimi N, Palermo F, Polosa R, Oliveri R, Maccarrone C, Palermo B, Mistretta A
Institute of Respiratory Diseases, University of Catania, Italy.
J Allergy Clin Immunol. 1989 May;83(5):921-5. doi: 10.1016/0091-6749(89)90106-1.
The exact mechanism of adenosine-induced bronchoconstriction in patients with asthma is unknown. Adenosine contraction of guinea pig trachea was antagonized by inhibitors of cyclooxygenase. The aim of this study was to investigate the effect of indomethacin (100 mg/day) on adenosine-induced bronchoconstriction in 14 asymptomatic patients with asthma. Airway response was evaluated as FEV1, and adenosine was administered as an aerosol diluted in 0.9% saline to produce a concentration range of 0.125 to 4 mg/ml. The dose of adenosine producing a 20% change in FEV1 (PD20) was calculated from the individual semilogarithmic dose-response curve; the results of PD20 were converted to log values for statistical analysis (Student's paired t test). The study was performed on 3 separate days. On the first day, the adenosine challenge was performed, and on subsequent days patients were pretreated with either placebo or indomethacin in a randomized, double-blind manner. Inhaled adenosine caused bronchoconstriction with a geometric mean PD20 of 0.71 mg (95% confidence limits, 0.44 to 1.16). After placebo, a geometric mean PD20 of 0.91 mg (95% confidence limits, 0.53 to 1.58) was obtained. Indomethacin pretreatment decreased adenosine hyperresponsiveness and shifted the dose-response curves of adenosine challenge to the right with a geometric mean PD20 of 1.28 mg (95% confidence limits, 0.64 to 2.56). The effect of indomethacin on adenosine bronchoconstriction (p less than 0.01 versus baseline; p less than 0.05 versus placebo) suggests an indirect mechanism of adenosine on inducing release of arachidonic acid derivatives. Inflammatory mediators inhibited by indomethacin may be involved in adenosine bronchoconstriction, even if this mechanism is not relevant.(ABSTRACT TRUNCATED AT 250 WORDS)
哮喘患者中腺苷诱发支气管收缩的确切机制尚不清楚。环氧化酶抑制剂可拮抗豚鼠气管的腺苷收缩作用。本研究的目的是调查吲哚美辛(100毫克/天)对14例无症状哮喘患者腺苷诱发支气管收缩的影响。气道反应以第一秒用力呼气容积(FEV1)进行评估,腺苷以稀释于0.9%盐水中的气雾剂形式给药,浓度范围为0.125至4毫克/毫升。根据个体半对数剂量反应曲线计算出使FEV1产生20%变化的腺苷剂量(PD20);PD20的结果转换为对数数值用于统计分析(学生配对t检验)。该研究在3个不同日期进行。第一天进行腺苷激发试验,随后几天患者以随机、双盲方式接受安慰剂或吲哚美辛预处理。吸入腺苷导致支气管收缩,几何平均PD20为0.71毫克(95%置信区间,0.44至1.16)。给予安慰剂后,几何平均PD20为0.91毫克(95%置信区间,0.53至1.58)。吲哚美辛预处理降低了腺苷高反应性,并使腺苷激发试验的剂量反应曲线右移,几何平均PD20为1.28毫克(95%置信区间,0.64至2.56)。吲哚美辛对腺苷支气管收缩的作用(与基线相比p<0.01;与安慰剂相比p<0.05)提示腺苷诱导花生四烯酸衍生物释放存在间接机制。即使该机制不相关,吲哚美辛抑制的炎症介质可能参与了腺苷支气管收缩。(摘要截短于250词)